Vericel Announces Expansion of MACI Coverage by UnitedHealthcare to Include Patella and Multiple Cartilage Defects in the Knee
Vericel Corporation (NASDAQ:VCEL) announced that UnitedHealthcare will expand its medical policy for MACI® to cover individuals with full-thickness cartilage defects in the patella and multiple knee defects. This policy change is set to take effect on February 1, 2021, providing coverage for over 26 million lives, making UnitedHealthcare the largest commercial payer in the U.S. CEO Nick Colangelo emphasized that this move aligns with MACI's label and will enhance patient access and support growth for the therapy in the future.
- Expansion of MACI coverage by UnitedHealthcare increases patient access.
- UnitedHealthcare covers more patients treated with MACI than other plans in the U.S.
- Policy aligns with MACI label and enhances clinical practice.
- None.
CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that UnitedHealthcare has expanded its medical policy for MACI® (autologous cultured chondrocytes on porcine collagen membrane) to include coverage for patients with symptomatic full-thickness cartilage defects in the patella and multiple cartilage defects in the knee. UnitedHealthcare is the largest commercial payer in the United States, covering more than 26 million lives, and more patients treated with MACI are covered by UnitedHealthcare than any other plan in the United States. The revised policy is effective February 1, 2021.
“We are very pleased that United Healthcare has expanded MACI coverage to include patients with patella and multiple cartilage defects in the knee, which is consistent with the MACI label and current clinical practice,” said Nick Colangelo, President and CEO of Vericel. “Since its launch, MACI has become a preferred treatment option, particularly for patients with cartilage defects on the patella, and this updated policy will increase patient access and support continued MACI growth in the years ahead.”
About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to
Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2020 Vericel Corporation. All rights reserved.
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements are subject to risks and uncertainties such as those described in Vericel’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
Investor Contacts:
Chad Rubin
Solebury Trout
crubin@troutgroup.com
+1 646-378-2947
FAQ
What is the recent announcement by Vericel regarding MACI coverage?
How many lives does UnitedHealthcare cover?
What impact does the MACI coverage expansion have on Vericel?
When will the expanded MACI coverage by UnitedHealthcare take effect?
What is MACI used for?
